Search

Your search keyword '"Tini, Giacomo"' showing total 309 results
Start Over Author "Tini, Giacomo"
309 results on '"Tini, Giacomo"'

1. Update on the diagnosis and treatment of pericardial diseases: a position paper of the Italian Society of Cardiology in collaboration with the study group on cardiomyopathies and pericardial diseases

Author

Imazio, Massimo, Collini, Valentino, Aimo, Alberto, Autore, Camillo, Bauce, Barbara, Biagini, Elena, Cappelli, Francesco, Castelletti, Silvia, D’Ascenzi, Flavio, De Gregorio, Cesare, Limongelli, Giuseppe, Marzo, Francesca, Merlo, Marco, Musumeci, Beatrice, Paolillo, Stefania, Tini, Giacomo, Pedrinelli, Roberto, Filardi, Pasquale Perrone, and Sinagra, Gianfranco

Published
2025
Full Text
View/download PDF

3. Update on the diagnosis and treatment of pericardial diseases: a position paper of the Italian Society of Cardiology in collaboration with the study group on cardiomyopathies and pericardial diseases

Author

Imazio, Massimo, Collini, Valentino, Aimo, Alberto, Autore, Camillo, Bauce, Barbara, Biagini, Elena, Cappelli, Francesco, Castelletti, Silvia, D’Ascenzi, Flavio, De Gregorio, Cesare, Limongelli, Giuseppe, Marzo, Francesca, Merlo, Marco, Musumeci, Beatrice, Paolillo, Stefania, Tini, Giacomo, Pedrinelli, Roberto, Filardi, Pasquale Perrone, and Sinagra, Gianfranco

Published
2024
Full Text
View/download PDF

5. Prognostic impact of hypertension and diabetes in patients with cardiac amyloidosis

Author

Argirò, Alessia, Biagioni, Giulia, Mazzoni, Carlotta, Zampieri, Mattia, Allinovi, Marco, Musumeci, Beatrice, Tini, Giacomo, Cianca, Alessandro, Merlo, Marco, Sinagra, Gianfranco, Porcari, Aldostefano, Pozzan, Marco, Canepa, Marco, Zanoletti, Margherita, Labate, Marianna Eleonora, Ponziani, Alberto, Saturi, Giulia, Ruotolo, Irene, Longhi, Simone, Biagini, Elena, Perfetto, Federico, and Cappelli, Francesco

Published
2025
Full Text
View/download PDF

6. Abstract 4144360: Neurohormonal therapies at baseline and follow-up and survival in patients with wild-type transthyretin cardiac amyloidosis

Author

Aimo, Alberto, Tini, Giacomo, Vergaro, Giuseppe, Milani, Paolo, Zampieri, Mattia, Caponetti, Angelo, Fabris, Francesca, Foli, Andrea, Mazzoni, Carlotta, Gagliardi, Christian, Longhi, Simone, Saturi, Giulia, Serenelli, Matteo, Fabbri, Gioele, De Michieli, Laura, Palmiero, Giuseppe, Ciliberti, Giuseppe, Carigi, Samuela, Mandoli, Giulia, Rella, Valeria, Mussinelli, Roberta, Cameli, Matteo, Marzo, Francesca, Limongelli, Giuseppe, Cipriani, Alberto, Perlini, Stefano, Obici, Laura, Perfetto, Federico, Sinagra, Gianfranco, Merlo, Marco, Musumeci, Beatrice, Biagini, Elena, Cappelli, Francesco, Palladini, Giovanni, Emdin, Michele, and Canepa, Marco

Published
2024
Full Text
View/download PDF

8. Clinical characteristics and outcome of end stage hypertrophic cardiomyopathy: Role of age and heart failure phenotypes

Author

Musumeci, Beatrice, Tini, Giacomo, Biagini, Elena, Merlo, Marco, Calore, Chiara, Ammirati, Enrico, Zampieri, Mattia, Russo, Domitilla, Grilli, Giulia, Santolamazza, Caterina, Vio, Riccardo, Rubino, Marta, Ditaranto, Raffaello, Del Franco, Annamaria, Sormani, Paola, Parisi, Vanda, Monda, Emanuele, Francia, Pietro, Cipriani, Alberto, Limongelli, Giuseppe, Sinagra, Gianfranco, Olivotto, Iacopo, Boni, Luca, and Autore, Camillo

Published
2024
Full Text
View/download PDF

9. Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy

Author

Porcari, Aldostefano, Fontana, Marianna, Canepa, Marco, Biagini, Elena, Cappelli, Francesco, Gagliardi, Christian, Longhi, Simone, Pagura, Linda, Tini, Giacomo, Dore, Franca, Bonfiglioli, Rachele, Bauckneht, Matteo, Miceli, Alberto, Girardi, Francesca, Martini, Anna Lisa, Barbati, Giulia, Costanzo, Egidio Natalino, Caponetti, Angelo Giuseppe, Paccagnella, Andrea, Sguazzotti, Maurizio, La Malfa, Giovanni, Zampieri, Mattia, Sciagrà, Roberto, Perfetto, Federico, Rowczenio, Dorota, Gilbertson, Janet, Hutt, David F., Hawkins, Philip N., Rapezzi, Claudio, Merlo, Marco, Sinagra, Gianfranco, and Gillmore, Julian D.

Published
2024
Full Text
View/download PDF

10. Electrocardiographic heterogeneity of patients with variant transthyretin amyloid cardiomyopathy: Genotype-phenotype correlations

Author

Russo, Domitilla, Cappelli, Francesco, Di Bella, Gianluca, Tini, Giacomo, Porcari, Aldostefano, Cipriani, Alberto, Canepa, Marco, Merlo, Marco, Licordari, Roberto, Vianello, Pier Filippo, Zampieri, Mattia, De Michieli, Laura, Scirpa, Riccardo, Perfetto, Federico, Sinagra, Gianfranco, Autore, Camillo, Rapezzi, Claudio, and Musumeci, Maria Beatrice

Published
2023
Full Text
View/download PDF

11. The Diagnostic Value of the 12-Lead ECG in Arrhythmogenic Left Ventricular Cardiomyopathy: Novel ECG Signs

Author

Calò, Leonardo, Crescenzi, Cinzia, Martino, Annamaria, Casella, Michela, Romeo, Fabiana, Cappelletto, Chiara, Bressi, Edoardo, Panattoni, Germana, Stolfo, Davide, Targetti, Mattia, Toso, Elisabetta, Musumeci, Maria Beatrice, Tini, Giacomo, Ciabatti, Michele, Stefanini, Matteo, Silvetti, Elisa, Stazi, Alessandra, Danza, Maria Ludovica, Rebecchi, Marco, Canestrelli, Stefano, Fedele, Elisa, Lanzillo, Chiara, Fusco, Armando, Sangiuolo, Federica Carla, Oliviero, Giada, Radesich, Cinzia, Perotto, Maria, Pieroni, Maurizio, Golia, Paolo, Mango, Ruggiero, Gasperetti, Alessio, Autore, Camillo, Merlo, Marco, de Ruvo, Ermenegildo, Russo, Antonio Dello, Olivotto, Iacopo, Sinagra, Gianfranco, and Gaita, Fiorenzo

Published
2023
Full Text
View/download PDF

12. Incidence and determinants of atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosis

Author

Fumagalli, Carlo, Zampieri, Mattia, Argirò, Alessia, Tassetti, Luigi, Rossi, Gabriele, Musumeci, Beatrice, Tini, Giacomo, Russo, Domitilla, Sclafani, Matteo, Cipriani, Alberto, Sinigiani, Giulio, Di Bella, Gianluca, Licordari, Roberto, Canepa, Marco, Vianello, Pier Filippo, Merlo, Marco, Porcari, Aldostefano, Rossi, Maddalena, Sinagra, Gianfranco, Rapezzi, Claudio, Di Mario, Carlo, Ungar, Andrea, Olivotto, Iacopo, Perfetto, Federico, and Cappelli, Francesco

Published
2023
Full Text
View/download PDF

14. Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value

Author

Cipriani, Alberto, De Michieli, Laura, Porcari, Aldostefano, Licchelli, Luca, Sinigiani, Giulio, Tini, Giacomo, Zampieri, Mattia, Sessarego, Eugenio, Argirò, Alessia, Fumagalli, Carlo, De Gaspari, Monica, Licordari, Roberto, Russo, Domitilla, Di Bella, Gianluca, Perfetto, Federico, Autore, Camillo, Musumeci, Beatrice, Canepa, Marco, Merlo, Marco, Sinagra, Gianfranco, Gregori, Dario, Iliceto, Sabino, Perazzolo Marra, Martina, Cappelli, Francesco, and Rapezzi, Claudio

Published
2022
Full Text
View/download PDF

16. Acute Myocarditis Associated With Desmosomal Gene Variants

Author

Ammirati, Enrico, Raimondi, Francesca, Piriou, Nicolas, Sardo Infirri, Loren, Mohiddin, Saidi A., Mazzanti, Andrea, Shenoy, Chetan, Cavallari, Ugo A., Imazio, Massimo, Aquaro, Giovanni Donato, Olivotto, Iacopo, Pedrotti, Patrizia, Sekhri, Neha, Van de Heyning, Caroline M., Broeckx, Glenn, Peretto, Giovanni, Guttmann, Oliver, Dellegrottaglie, Santo, Scatteia, Alessandra, Gentile, Piero, Merlo, Marco, Goldberg, Randal I., Reyentovich, Alex, Sciamanna, Christopher, Klaassen, Sabine, Poller, Wolfgang, Trankle, Cory R., Abbate, Antonio, Keren, Andre, Horowitz-Cederboim, Smadar, Cadrin-Tourigny, Julia, Tadros, Rafik, Annoni, Giuseppe A., Bonoldi, Emanuela, Toquet, Claire, Marteau, Lara, Probst, Vincent, Trochu, Jean Noël, Kissopoulou, Antheia, Grosu, Aurelia, Kukavica, Deni, Trancuccio, Alessandro, Gil, Cristina, Tini, Giacomo, Pedrazzini, Matteo, Torchio, Margherita, Sinagra, Gianfranco, Gimeno, Juan Ramón, Bernasconi, Davide, Valsecchi, Maria Grazia, Klingel, Karin, Adler, Eric D., Camici, Paolo G., and Cooper, Leslie T., Jr.

Published
2022
Full Text
View/download PDF

17. Critical approach to the 2023 European Society of Cardiology guidelines on cardiomyopathies: a document by the Working Group on Myocardial and Pericardial Diseases of the Italian Society of Cardiology.

Author

Merlo, Marco, Pio Loco detto Gava, Carola, Perotto, Maria, Aimo, Alberto, Autore, Camillo, Bauce, Barbara, Biagini, Elena, Cappelli, Francesco, Castelletti, Silvia, D'Ascenzi, Flavio, de Gregorio, Cesare, Limongelli, Giuseppe, Marzo, Francesca, Musumeci, Beatrice, Tini, Giacomo, Pedrinelli, Roberto, Perrone Filardi, Pasquale, Sinagra, Gianfranco, and Imazio, Massimo

Published
2025
Full Text
View/download PDF

20. Unveiling the Future of Cardiac Care: A Review of Gene Therapy in Cardiomyopathies.

Author

Venturiello, Damiano, Tiberi, Pier Giorgio, Perulli, Francesco, Nardoianni, Giulia, Guida, Leonardo, Barsali, Carlo, Terrone, Carlo, Cianca, Alessandro, Lustri, Camilla, Sclafani, Matteo, Tini, Giacomo, Barbato, Emanuele, and Musumeci, Beatrice

Subjects
FRIEDREICH'S ataxia, GENE therapy, GENOME editing, GLYCOGEN storage disease type II, DUCHENNE muscular dystrophy
Abstract

For years, the treatment of many cardiomyopathies has been solely focused on symptom management. However, cardiomyopathies have a genetic substrate, and directing therapy towards the pathophysiology rather than the epiphenomenon of the disease may be a winning strategy. Gene therapy involves the insertion of genes or the modification of existing ones and their regulatory elements through strategies like gene replacement and gene editing. Recently, gene therapy for cardiac amyloidosis and Duchenne muscular dystrophy has received approval, and important clinical trials are currently evaluating gene therapy methods for rare heart diseases like Friedreich's Ataxia, Danon disease, Fabry disease, and Pompe Disease. Furthermore, favorable results have been noted in animal studies receiving gene therapy for hypertrophic, dilated, and arrhythmogenic cardiomyopathy. This review discusses gene therapy methods, ongoing clinical trials, and future goals in this area. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Management of overlapping immune-related myocarditis, myositis, and myasthenia in a young patient with advanced NSCLC: a case report.

Author

Mariniello, Monica, Arrivi, Giulia, Tufano, Laura, Lauletta, Antonio, Moro, Mirella, Tini, Giacomo, Garibaldi, Matteo, Giusti, Raffaele, and Mazzuca, Federica

Subjects
CORONARY care units, DRUG side effects, NON-small-cell lung carcinoma, PHYSICIANS, CONSCIOUSNESS raising
Abstract

Immunotherapy is increasingly used in advanced non-small-cell lung cancer (NSCLC), offering a significant anti-tumor response, as well as causing rising immune-related adverse effects. The incidence of immune checkpoint inhibitorinduced myocarditis-myositis-myasthenia gravis is increasing and particularly concerning due to its high mortality rate. Prompt recognition, diagnosis, and management are crucial. A 40-year-old patient, diagnosed with stage IV nononcogene addicted lung adenocarcinoma, with nivolumab-ipilimumab-chemotherapy as first-line treatment, developed a rare myocarditis-myositis-myasthenia gravis overlap syndrome. Following the treatment, the patient presented with flu-like symptoms and chest pain and subsequently transferred to the cardiac intensive care unit. The physical examination revealed a visual acuity deficit, diplopia, ophthalmoparesis, ptosis, mydriasis, dysphagia, dyspnea, headache, nausea, dry mouth, asthenia, myalgia, and muscle weakness. Imaging and laboratory tests confirmed the triad, showing an elevation of hs-cTnI and CK and positive results for anti-SAE1 and anti-PL-7 Abs. ECG revealed ST segment elevation and RBBB. The echo showed hyperechogenicity of the inferolateral wall, pericardial detachment, and thickening. The cardiac MRI demonstrated hypokinesia, edema, subepicardial LGE, and pericardial effusion. Muscle biopsy revealed muscle fiber necrosis and regeneration with B and T lymphocytic endomysial inflammatory infiltrate and expression of MHC-I. Treatment with oral prednisone, pyridostigmine, and IV Igs was started due to poor clinical response followed by methylprednisolone. Despite stopping immunotherapy, the patient continued to benefit from it, as highlighted on subsequent reevaluation CT scans by partial disease response, and as the patient was in complete remission, we decided to resume chemotherapy by omitting immunotherapy. At the radiological control following the four cycles of double CHT and during CHT maintenance, there was a further reduction of the disease. This report aims to raise awareness among physicians about these serious side effects. A multidisciplinary approach led to clinical improvement and early intervention, optimizing patient outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis

Author

Muller, Steven A, Peiró-Aventin, Belén, Biagioni, Giulia, Tini, Giacomo, Saturi, Giulia, Kronberger, Christina, Achten, Anouk, Dobner, Stephan, Te Rijdt, Wouter P, Gasperetti, Alessio, Te Riele, Anneline S J M, Varrà, Guerino G, Ponziani, Alberto, Hirsch, Alexander, Porcari, Aldostefano, van der Meer, Manon G, Zampieri, Mattia, van der Harst, Pim, Kammerlander, Andreas, Biagini, Elena, van Tintelen, J Peter, Barbato, Emanuele, Asselbergs, Folkert W, Menale, Silvia, Gräni, Christoph, Merlo, Marco, Michels, Michelle, Knackstedt, Christian, Nitsche, Christian, Longhi, Simone, Musumeci, Beatrice, Cappelli, Francesco, Garcia-Pavia, Pablo, Oerlemans, Marish I F J, Muller, Steven A, Peiró-Aventin, Belén, Biagioni, Giulia, Tini, Giacomo, Saturi, Giulia, Kronberger, Christina, Achten, Anouk, Dobner, Stephan, Te Rijdt, Wouter P, Gasperetti, Alessio, Te Riele, Anneline S J M, Varrà, Guerino G, Ponziani, Alberto, Hirsch, Alexander, Porcari, Aldostefano, van der Meer, Manon G, Zampieri, Mattia, van der Harst, Pim, Kammerlander, Andreas, Biagini, Elena, van Tintelen, J Peter, Barbato, Emanuele, Asselbergs, Folkert W, Menale, Silvia, Gräni, Christoph, Merlo, Marco, Michels, Michelle, Knackstedt, Christian, Nitsche, Christian, Longhi, Simone, Musumeci, Beatrice, Cappelli, Francesco, Garcia-Pavia, Pablo, and Oerlemans, Marish I F J

Abstract

AIMS: The 2021 European Society of Cardiology (ESC) screening recommendations for individuals carrying a pathogenic transthyretin amyloidosis variant (ATTRv) are based on expert opinion. We aimed to (i) determine the penetrance of ATTRv cardiomyopathy (ATTRv-CM) at baseline; (ii) examine the value of serial evaluation; and (iii) establish the yield of first-line diagnostic tests (i.e. electrocardiogram, echocardiogram, and laboratory tests) as per 2021 ESC position statement.METHODS AND RESULTS: We included 159 relatives (median age 55.6 [43.2-65.9] years, 52% male) at risk for ATTRv-CM from 10 centres. The primary endpoint, ATTRv-CM diagnosis, was defined as the presence of (i) cardiac tracer uptake in bone scintigraphy; or (ii) transthyretin-positive cardiac biopsy. The secondary endpoint was a composite of heart failure (New York Heart Association class ≥II) and pacemaker-requiring conduction disorders. At baseline, 40/159 (25%) relatives were diagnosed with ATTRv-CM. Of those, 20 (50%) met the secondary endpoint. Indication to screen (≤10 years prior to predicted disease onset and absence of extracardiac amyloidosis) had an excellent negative predictive value (97%). Other pre-screening predictors for ATTRv-CM were infrequently identified variants and male sex. Importantly, 13% of relatives with ATTRv-CM did not show any signs of cardiac involvement on first-line diagnostic tests. The yield of serial evaluation (n = 41 relatives; follow-up 3.1 [2.2-5.2] years) at 3-year interval was 9.4%.CONCLUSIONS: Screening according to the 2021 ESC position statement performs well in daily clinical practice. Clinicians should adhere to repeating bone scintigraphy after 3 years, as progressing to ATTRv-CM without signs of ATTRv-CM on first-line diagnostic tests or symptoms is common.

Published
2024

24. Arterial Hypertension

Author

Spallarossa, Paolo, Tini, Giacomo, Lenihan, Daniel, Giordano, Antonio, Series Editor, Russo, Antonio, editor, Novo, Giuseppina, editor, Lancellotti, Patrizio, editor, and Pinto, Fausto J., editor

Published
2019
Full Text
View/download PDF

26. A contemporary update on cancer and takotsubo syndrome

Author

Tini, Giacomo, primary, Arcari, Luca, additional, Mistrulli, Raffaella, additional, Follesa, Federico, additional, Cianca, Alessandro, additional, Sclafani, Matteo, additional, Tocci, Giuliano, additional, Spallarossa, Paolo, additional, Battistoni, Allegra, additional, Cacciotti, Luca, additional, Musumeci, Beatrice, additional, and Barbato, Emanuele, additional

Published
2024
Full Text
View/download PDF

27. Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis.

Author

Muller, Steven A., Peiró‐Aventin, Belén, Biagioni, Giulia, Tini, Giacomo, Saturi, Giulia, Kronberger, Christina, Achten, Anouk, Dobner, Stephan, te Rijdt, Wouter P., Gasperetti, Alessio, te Riele, Anneline S.J.M., Varrà, Guerino G., Ponziani, Alberto, Hirsch, Alexander, Porcari, Aldostefano, van der Meer, Manon G., Zampieri, Mattia, van der Harst, Pim, Kammerlander, Andreas, and Biagini, Elena

Subjects
RADIONUCLIDE imaging, MEDICAL screening, DIAGNOSIS methods, HEART failure, MEDICAL personnel, CARDIAC amyloidosis
Abstract

Aims: The 2021 European Society of Cardiology (ESC) screening recommendations for individuals carrying a pathogenic transthyretin amyloidosis variant (ATTRv) are based on expert opinion. We aimed to (i) determine the penetrance of ATTRv cardiomyopathy (ATTRv‐CM) at baseline; (ii) examine the value of serial evaluation; and (iii) establish the yield of first‐line diagnostic tests (i.e. electrocardiogram, echocardiogram, and laboratory tests) as per 2021 ESC position statement. Methods and results: We included 159 relatives (median age 55.6 [43.2–65.9] years, 52% male) at risk for ATTRv‐CM from 10 centres. The primary endpoint, ATTRv‐CM diagnosis, was defined as the presence of (i) cardiac tracer uptake in bone scintigraphy; or (ii) transthyretin‐positive cardiac biopsy. The secondary endpoint was a composite of heart failure (New York Heart Association class ≥II) and pacemaker‐requiring conduction disorders. At baseline, 40/159 (25%) relatives were diagnosed with ATTRv‐CM. Of those, 20 (50%) met the secondary endpoint. Indication to screen (≤10 years prior to predicted disease onset and absence of extracardiac amyloidosis) had an excellent negative predictive value (97%). Other pre‐screening predictors for ATTRv‐CM were infrequently identified variants and male sex. Importantly, 13% of relatives with ATTRv‐CM did not show any signs of cardiac involvement on first‐line diagnostic tests. The yield of serial evaluation (n = 41 relatives; follow‐up 3.1 [2.2–5.2] years) at 3‐year interval was 9.4%. Conclusions: Screening according to the 2021 ESC position statement performs well in daily clinical practice. Clinicians should adhere to repeating bone scintigraphy after 3 years, as progressing to ATTRv‐CM without signs of ATTRv‐CM on first‐line diagnostic tests or symptoms is common. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Old and new therapeutic solutions in the treatment of hypertrophic cardiomyopathy

Author

Autore, Camillo, Francia, Pietro, Tini, Giacomo, and Musumeci, Beatrice

Subjects
myosin inhibitors, alcohol ablation, hypertrophic cardiomyopathy, myectomy, outflow tract obstruction, Cardiology and Cardiovascular Medicine
Abstract

Hypertrophic cardiomyopathy (HCM) is a genetic disease of the myocardium that is relatively common in the general population, with an autosomal dominant inheritance as a genetic basis. Clinical and natural history pathways can be very different among patients with HCM. Treatment strategies have made very important advances in the last two decades, especially reducing cases of sudden death through effective risk stratification and the use of implantable defibrillators. Heart failure has become the predominant cause of morbidity and mortality in patients with HCM, being responsible for as many as 60% of disease-related deaths. HCM is most often characterized by the presence of left ventricular outflow tract (LVOT) obstruction, and this obstruction is the most frequent cause of impaired exercise tolerance in HCM and a strong independent predictor of heart failure progression and mortality. The different treatment strategies of LVOT obstruction in HCM are discussed below: surgical, invasive, and the more recent pharmacological.

Published
2023
Full Text
View/download PDF

30. Real‐world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population

Author

Bertero, Edoardo, primary, Chiti, Chiara, additional, Schiavo, Maria Alessandra, additional, Tini, Giacomo, additional, Costa, Paolo, additional, Todiere, Giancarlo, additional, Mabritto, Barbara, additional, Dei, Lorenzo‐Lupo, additional, Giannattasio, Alessia, additional, Mariani, Davide, additional, Lofiego, Carla, additional, Santolamazza, Caterina, additional, Monda, Emanuele, additional, Quarta, Giovanni, additional, Barbisan, Davide, additional, Mandoli, Giulia Elena, additional, Mapelli, Massimo, additional, Sguazzotti, Maurizio, additional, Negri, Francesco, additional, De Vecchi, Simona, additional, Ciabatti, Michele, additional, Tomasoni, Daniela, additional, Mazzanti, Andrea, additional, Marzo, Francesca, additional, de Gregorio, Cesare, additional, Raineri, Claudia, additional, Vianello, Pier Filippo, additional, Marchi, Alberto, additional, Biagioni, Giulia, additional, Insinna, Eleonora, additional, Parisi, Vanda, additional, Ditaranto, Raffaello, additional, Barison, Andrea, additional, Giammaresi, Andrea, additional, De Ferrari, Gaetano Maria, additional, Priori, Silvia, additional, Metra, Marco, additional, Pieroni, Maurizio, additional, Patti, Giuseppe, additional, Imazio, Massimo, additional, Perugini, Enrica, additional, Agostoni, Piergiuseppe, additional, Cameli, Matteo, additional, Merlo, Marco, additional, Sinagra, Gianfranco, additional, Senni, Michele, additional, Limongelli, Giuseppe, additional, Ammirati, Enrico, additional, Vagnarelli, Fabio, additional, Crotti, Lia, additional, Badano, Luigi, additional, Calore, Chiara, additional, Gabrielli, Domenico, additional, Re, Federica, additional, Musumeci, Giuseppe, additional, Emdin, Michele, additional, Barbato, Emanuele, additional, Musumeci, Beatrice, additional, Autore, Camillo, additional, Biagini, Elena, additional, Porto, Italo, additional, Olivotto, Iacopo, additional, and Canepa, Marco, additional

Published
2023
Full Text
View/download PDF

31. European Society of Cardiology Core Curriculum for Cardio‐Oncology

Author

López‐Fernández, Teresa, primary, Farmakis, Dimitrios, additional, Ameri, Pietro, additional, Asteggiano, Riccardo, additional, de Azambuja, Evandro, additional, Aznar, Marianne, additional, Barac, Ana, additional, Bayes‐Genis, Antoni, additional, Bax, Jeroen J., additional, Bergler‐Klein, Jutta, additional, Boriani, Giuseppe, additional, Celutkiene, Jelena, additional, Coats, Andrew, additional, Cohen‐Solal, Alain, additional, Córdoba, Raúl, additional, Cosyns, Bernard, additional, Filippatos, Gerasimos, additional, Fox, Kevin, additional, Gulati, Geeta, additional, Inciardi, Riccardo M., additional, Lee, Geraldine, additional, Mamas, Mamas A., additional, Novo, Giuseppina, additional, Plummer, Chris, additional, Psyrri, Amanda, additional, Rakisheva, Amina, additional, Suter, Thomas, additional, Tini, Giacomo, additional, Tocchetti, Carlo Gabriele, additional, Toutouzas, Konstantinos, additional, Wilhelm, Matthias, additional, Metra, Marco, additional, Lyon, Alexander R., additional, and Rosano, Giuseppe M. C., additional

Published
2023
Full Text
View/download PDF

39. Real‐world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population.

Author

Bertero, Edoardo, Chiti, Chiara, Schiavo, Maria Alessandra, Tini, Giacomo, Costa, Paolo, Todiere, Giancarlo, Mabritto, Barbara, Dei, Lorenzo‐Lupo, Giannattasio, Alessia, Mariani, Davide, Lofiego, Carla, Santolamazza, Caterina, Monda, Emanuele, Quarta, Giovanni, Barbisan, Davide, Mandoli, Giulia Elena, Mapelli, Massimo, Sguazzotti, Maurizio, Negri, Francesco, and De Vecchi, Simona

Subjects
HYPERTROPHIC cardiomyopathy, VENTRICULAR outflow obstruction, VENTRICULAR ejection fraction
Abstract

Aims: In the EXPLORER‐HCM trial, mavacamten reduced left ventricular outflow tract obstruction (LVOTO) and improved functional capacity of symptomatic hypertrophic obstructive cardiomyopathy (HOCM) patients. We sought to define the potential use of mavacamten by comparing real‐world HOCM patients with those enrolled in EXPLORER‐HCM and assessing their eligibility to treatment. Methods and results: We collected information on HOCM patients followed up at 25 Italian HCM outpatient clinics and with significant LVOTO (i.e. gradient ≥30 mmHg at rest or ≥50 mmHg after Valsalva manoeuvre or exercise) despite pharmacological or non‐pharmacological therapy. Pharmacological or non‐pharmacological therapy resolved LVOTO in 1044 (61.2%) of the 1706 HOCM patients under active follow‐up, whereas 662 patients (38.8%) had persistent LVOTO. Compared to the EXPLORER‐HCM trial population, these real‐world HOCM patients were older (62.1 ± 14.3 vs. 58.5 ± 12.2 years, p = 0.02), had a lower body mass index (26.8 ± 5.3 vs. 29.7 ± 4.9 kg/m2, p < 0.0001) and a more frequent history of atrial fibrillation (21.5% vs. 9.8%, p = 0.027). At echocardiography, they had lower left ventricular ejection fraction (LVEF, 66 ± 7% vs. 74 ± 6%, p < 0.0001), higher left ventricular outflow tract gradients at rest (60 ± 27 vs. 52 ± 29 mmHg, p = 0.003), and larger left atrial volume index (49 ± 16 vs. 40 ± 12 ml/m2, p < 0.0001). Overall, 324 (48.9%) would have been eligible for enrolment in the EXPLORER‐HCM trial and 339 (51.2%) for treatment with mavacamten according to European guidelines. Conclusions: Real‐world HOCM patients differ from the EXPLORER‐HCM population for their older age, lower LVEF and larger atrial volume, potentially reflecting a more advanced stage of the disease. About half of real‐world HOCM patients were found eligible to mavacamten. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. From the phenotype to precision medicine: an update on the cardiomyopathies diagnostic workflow

Author

Autore, Camillo, primary, Bariani, Riccardo, additional, Bauce, Barbara, additional, Biagini, Elena, additional, Canepa, Marco, additional, Castelletti, Silvia, additional, Crotti, Lia, additional, Limongelli, Giuseppe, additional, Merlo, Marco, additional, Monda, Emanuele, additional, Pio Loco detto Gava, Carola, additional, Parisi, Vanda, additional, Tini, Giacomo, additional, and Imazio, Massimo, additional

Published
2023
Full Text
View/download PDF

43. Long QTc in hypertrophic cardiomyopathy: A consequence of structural myocardial damage or a distinct genetic disease?

Author

Cava, Francesco, primary, Micolonghi, Caterina, additional, Musumeci, Maria Beatrice, additional, Petrucci, Simona, additional, Savio, Camilla, additional, Fabiani, Marco, additional, Tini, Giacomo, additional, Germani, Aldo, additional, Libi, Fabio, additional, Rossi, Carla, additional, Visco, Vincenzo, additional, Pizzuti, Antonio, additional, Volpe, Massimo, additional, Autore, Camillo, additional, Rubattu, Speranza, additional, and Piane, Maria, additional

Published
2023
Full Text
View/download PDF

45. Risk stratification in transthyretin-related cardiac amyloidosis

Author

Scirpa, Riccardo, Cittadini, Edoardo, Mazzocchi, Lorenzo, Tini, Giacomo, Sclafani, Matteo, Russo, Domitilla, Imperatrice, Andrea, Tropea, Alessandro, Autore, Camillo, and Musumeci, Beatrice

Subjects
arrhythmias, cardiac amyloidosis, heart failure, natural history, risk stratification, transthyretin, Cardiology and Cardiovascular Medicine
Abstract

Transthyretin related cardiac amyloidosis (TTR-CA) is an infiltrative cardiomyopathy that cause heart failure with preserved ejection fraction, mainly in aging people. Due to the introduction of a non invasive diagnostic algorithm, this disease, previously considered to be rare, is increasingly recognized. The natural history of TTR-CA includes two different stages: a presymptomatic and a symptomatic stage. Due to the availability of new disease-modifying therapies, the need to reach a diagnosis in the first stage has become impelling. While in variant TTR-CA an early identification of the disease may be obtained with a genetic screening in proband's relatives, in the wild-type form it represents a challenging issue. Once the diagnosis has been made, in order to identifying patients with a higher risk of cardiovascular events and death it is necessary to focus on risk stratification. Two prognostic scores have been proposed both based on biomarkers and laboratory findings. However, a multiparametric approach combining information from electrocardiogram, echocardiogram, cardiopulmonary exercise test and cardiac magnetic resonance may be warranted for a more comprehensive risk prediction. In this review, we aim at evaluating a step by step risk stratification, providing a clinical diagnostic and prognostic approach for the management of patients with TTR-CA.

Published
2023
Full Text
View/download PDF

46. Diagnostic pathways to wild‐type transthyretin amyloid cardiomyopathy: a multicentre network study

Author

Tini, Giacomo, primary, Milani, Paolo, additional, Zampieri, Mattia, additional, Caponetti, Angelo G., additional, Fabris, Francesca, additional, Foli, Andrea, additional, Argirò, Alessia, additional, Mazzoni, Carlotta, additional, Gagliardi, Christian, additional, Longhi, Simone, additional, Saturi, Giulia, additional, Vergaro, Giuseppe, additional, Aimo, Alberto, additional, Russo, Domitilla, additional, Varrà, Guerino G., additional, Serenelli, Matteo, additional, Fabbri, Gioele, additional, De Michieli, Laura, additional, Palmiero, Giuseppe, additional, Ciliberti, Giuseppe, additional, Carigi, Samuela, additional, Sessarego, Eugenio, additional, Mandoli, Giulia E., additional, Ricci Lucchi, Giulia, additional, Rella, Valeria, additional, Monti, Enrico, additional, Gardini, Elisa, additional, Bartolotti, Michela, additional, Crotti, Lia, additional, Merli, Elisa, additional, Mussinelli, Roberta, additional, Vianello, Pier Filippo, additional, Cameli, Matteo, additional, Marzo, Francesca, additional, Guerra, Federico, additional, Limongelli, Giuseppe, additional, Cipriani, Alberto, additional, Perlini, Stefano, additional, Obici, Laura, additional, Perfetto, Federico, additional, Autore, Camillo, additional, Porto, Italo, additional, Rapezzi, Claudio, additional, Sinagra, Gianfranco, additional, Merlo, Marco, additional, Musumeci, Beatrice, additional, Emdin, Michele, additional, Biagini, Elena, additional, Cappelli, Francesco, additional, Palladini, Giovanni, additional, and Canepa, Marco, additional

Published
2023
Full Text
View/download PDF

47. Diagnostic Delay in Arrhythmogenic Cardiomyopathy

Author

Tini, Giacomo, primary, Graziosi, Maddalena, additional, Musumeci, Beatrice, additional, Targetti, Mattia, additional, Russo, Domitilla, additional, Parisi, Vanda, additional, Argirò, Alessia, additional, Ditaranto, Raffaello, additional, Leone, Ornella, additional, Autore, Camillo, additional, Olivotto, Iacopo, additional, and Biagini, Elena, additional

Published
2023
Full Text
View/download PDF

50. 310 CLINICAL COURSE AND CHARACTERISTICS OF ADVANCED HEART FAILURE ASSOCIATED WITH ARRHYTHMOGENIC CARDIOMYOPATHY

Author

Tini, Giacomo, primary, Graziosi, Maddalena, additional, Musumeci, Beatrice, additional, Targetti, Mattia, additional, Parisi, Vanda, additional, Russo, Domitilla, additional, Argirò, Alessia, additional, Ditaranto, Raffaello, additional, Basile, Ludovica, additional, Imperatrice, Andrea, additional, Zampieri, Mattia, additional, Sclafani, Matteo, additional, Leone, Ornella, additional, Autore, Camillo, additional, Olivotto, Iacopo, additional, and Biagini, Elena, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results